Prenat Diagn. 2013 Jul;33(7):682-7. doi: 10.1002/pd.4093. Epub 2013 Mar 22.
RASSF1A in maternal plasma as a molecular marker of preeclampsia (Προεκλαμψία και πρώιμη διάγνωση προεκλαμψίας)
Papantoniou N, Bagiokos V, Agiannitopoulos K, Kolialexi A, Destouni A, Tounta G, Kanavakis E, Antsaklis A, Mavrou A.
Source
1st Department of Obstetrics and Gynaecology, Athens University School of Medicine, Athens, Greece.
Abstract
OBJECTIVES:
This study aimed to quantitate cell free (cf) and cell free fetal (cff) DNA in maternal plasma by determining RASSF1A levels before and after enzyme digestion in women who subsequently developed preeclampsia (PE)(προεκλαμψια) and compare them with uncomplicated pregnancies.(πρώιμη διάγνωση προεκλαμψίας)
METHODS:
Twenty-four samples from pregnant women who developed PE(προεκλαμψία) and 48 samples from women with uncomplicated pregnancies were analysed. Blood samples were obtained at 11-13 weeks. cfDNA was determined by quantifying RASSF1A using qRT-PCR. A second qRT-PCR was performed following methylation-sensitive enzyme digestion by BstUI, to quantitate hypermethylated RASSF1A sequences of fetal origin. ACTB gene was used as control to confirm complete enzyme digestion.
RESULTS:
CONCLUSIONS:
The study demonstrates potential use of cfDNA and cffDNA in maternal plasma as markers for the early prediction of women at risk for PE( πρώιμη διάγνωση προεκλαμψίας). © 2013 John Wiley & Sons, Ltd.
ACKNOWLEDGEMENTS
The first two authors contributed equally to the study and should be both considered as first author.
Το παρόν άρθρο εκπονήθηκε στα πλαίσια της συγγραφής της Διδακτορικής μου διατριβής με θέμα την Πρώιμη ανίχνευση/διάγνωση της Προεκλαμψίας και δημοσιεύθηκε στο περιοδικό Prenatal Diagnosis Prenatal 2013, 33, 682–687
Article first published online: 22 MAR 2013